SG10201703451RA - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
SG10201703451RA
SG10201703451RA SG10201703451RA SG10201703451RA SG10201703451RA SG 10201703451R A SG10201703451R A SG 10201703451RA SG 10201703451R A SG10201703451R A SG 10201703451RA SG 10201703451R A SG10201703451R A SG 10201703451RA SG 10201703451R A SG10201703451R A SG 10201703451RA
Authority
SG
Singapore
Prior art keywords
antiviral compounds
antiviral
compounds
Prior art date
Application number
SG10201703451RA
Inventor
John O Link
Jeromy J Cottell
Martin Teresa Alejandra Trejo
Elizabeth M Bacon
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of SG10201703451RA publication Critical patent/SG10201703451RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
SG10201703451RA 2012-05-16 2013-05-15 Antiviral compounds SG10201703451RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds

Publications (1)

Publication Number Publication Date
SG10201703451RA true SG10201703451RA (en) 2017-06-29

Family

ID=49581469

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407533SA SG11201407533SA (en) 2012-05-16 2013-05-15 Antiviral compounds
SG10201703451RA SG10201703451RA (en) 2012-05-16 2013-05-15 Antiviral compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407533SA SG11201407533SA (en) 2012-05-16 2013-05-15 Antiviral compounds

Country Status (19)

Country Link
US (5) US20130309196A1 (en)
EP (2) EP3239153B1 (en)
JP (2) JP6209209B2 (en)
KR (2) KR102078233B1 (en)
CN (3) CN109970749A (en)
AU (3) AU2013262874B2 (en)
BR (1) BR112014028221B1 (en)
CA (1) CA2873485C (en)
EA (2) EA028026B1 (en)
ES (2) ES2628350T3 (en)
HK (2) HK1205126A1 (en)
IL (1) IL235645A0 (en)
IN (1) IN2014MN02459A (en)
MX (1) MX362060B (en)
PL (2) PL3239153T3 (en)
PT (2) PT2850085T (en)
SG (2) SG11201407533SA (en)
SI (2) SI2850085T1 (en)
WO (1) WO2013173488A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP3699176A3 (en) 2010-11-17 2020-11-18 Gilead Pharmasset LLC Antiviral compounds
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EA201690473A1 (en) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи COMBINED COMPOSITION OF TWO ANTI-VIRUS COMPOUNDS
WO2015030854A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI679203B (en) * 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 Processes for preparing antiviral compounds
TWI721947B (en) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 Solid forms of an antiviral compound
EP3473630B1 (en) * 2014-07-02 2021-01-13 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
EP3939985A1 (en) 2014-12-26 2022-01-19 Emory University Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
US9957279B2 (en) 2016-05-05 2018-05-01 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of Hepatitis C virus (HCV) inhibitors
AU2017271990B2 (en) 2016-05-27 2019-12-19 Gilead Sciences, Inc. Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
WO2018006811A1 (en) * 2016-07-08 2018-01-11 深圳市塔吉瑞生物医药有限公司 Substituted imidazolyl compound and pharmaceutical composition thereof
CN106220639A (en) * 2016-07-22 2016-12-14 上海众强药业有限公司 A kind of Wei Patawei intermediate novel crystal forms
CN107759577B (en) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 GS5816 intermediate, preparation method and application
CN107501280A (en) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 A kind of Wei Patawei synthetic method
RU2020116571A (en) 2017-12-07 2021-11-22 Эмори Юниверсити N4-HYDROXYCYTIDINE AND DERIVATIVES AND RELATED ANTIVIRAL USES
KR20210093951A (en) 2018-11-21 2021-07-28 이난타 파마슈티칼스, 인코포레이티드 Functionalized Heterocycles as Antiviral Agents
CN111018870B (en) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 Preparation method of vipatavir intermediate
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US20230257348A1 (en) * 2020-08-18 2023-08-17 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
US20220411434A1 (en) * 2021-05-21 2022-12-29 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE10399025I2 (en) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Active substance precursors of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP4558314B2 (en) * 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド Viral polymerase inhibitor
WO2004099241A1 (en) 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Hepatitis c virus ns5b polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
PL1778702T3 (en) 2004-07-16 2011-12-30 Gilead Sciences Inc Antiviral compounds
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010008650A (en) 2008-02-12 2010-08-30 Bristol Myers Squibb Co Hepatitis c virus inhibitors.
KR101492672B1 (en) 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CN102300461B (en) 2008-12-03 2015-04-22 普雷西迪奥制药公司 Inhibitors Of Hcv Ns5a
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
EA027493B1 (en) * 2009-05-13 2017-07-31 Джилид Фармассет Ллс Intermediates for preparing an antiviral compound
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013515068A (en) 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション Fused tricyclic compounds for the treatment of viral diseases and methods of use thereof
KR20130008040A (en) 2010-03-09 2013-01-21 머크 샤프 앤드 돔 코포레이션 Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP3699176A3 (en) * 2010-11-17 2020-11-18 Gilead Pharmasset LLC Antiviral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
DK2907816T3 (en) * 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
CA2873485C (en) 2020-05-05
CA2873485A1 (en) 2013-11-21
CN109970749A (en) 2019-07-05
KR102078233B1 (en) 2020-02-17
CN106432254B (en) 2018-12-28
ES2738012T3 (en) 2020-01-17
PT3239153T (en) 2019-07-30
US20140316144A1 (en) 2014-10-23
US20160115175A1 (en) 2016-04-28
EA028026B1 (en) 2017-09-29
HK1245262B (en) 2020-01-10
AU2017248566A1 (en) 2017-11-09
SI3239153T1 (en) 2019-08-30
BR112014028221B1 (en) 2022-05-03
IN2014MN02459A (en) 2015-07-10
MX362060B (en) 2019-01-07
US20130309196A1 (en) 2013-11-21
HK1205126A1 (en) 2015-12-11
PL3239153T3 (en) 2019-09-30
AU2013262874B2 (en) 2017-11-02
CN106432254A (en) 2017-02-22
MX2014013660A (en) 2015-04-17
PT2850085T (en) 2017-06-26
EP2850085B1 (en) 2017-03-15
JP6209209B2 (en) 2017-10-04
AU2013262874A2 (en) 2015-01-22
US10800789B2 (en) 2020-10-13
US9682989B2 (en) 2017-06-20
JP2015517527A (en) 2015-06-22
AU2013262874A1 (en) 2014-12-11
US20170342085A1 (en) 2017-11-30
CN104487442B (en) 2016-10-26
EA201492002A1 (en) 2015-11-30
SG11201407533SA (en) 2014-12-30
US20190337960A1 (en) 2019-11-07
EP3239153B1 (en) 2019-05-08
EP2850085A1 (en) 2015-03-25
PL2850085T3 (en) 2017-10-31
JP6408656B2 (en) 2018-10-17
KR20200017557A (en) 2020-02-18
AU2019204423A1 (en) 2019-07-11
EP3239153A1 (en) 2017-11-01
EA201790963A1 (en) 2018-02-28
CN104487442A (en) 2015-04-01
BR112014028221A2 (en) 2020-10-27
WO2013173488A1 (en) 2013-11-21
IL235645A0 (en) 2015-02-01
KR20150008908A (en) 2015-01-23
SI2850085T1 (en) 2017-08-31
ES2628350T3 (en) 2017-08-02
JP2017160276A (en) 2017-09-14
EA034749B1 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
HK1245263A1 (en) Antiviral compounds
HRP20171351T1 (en) Rsv antiviral compounds
IL252345A0 (en) Antiviral compounds
SG10201703451RA (en) Antiviral compounds
AP2014007810A0 (en) Imidazopyrrolidinone compounds
EP2925129A4 (en) Pro-neurogenic compounds
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) Pro-neurogenic compounds
HK1208677A1 (en) Antiviral compounds with an imidazole - biphenyl - imidazole core --
EP2828262A4 (en) Imidazotriazinone compounds
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1199454A1 (en) Antiviral compounds
HK1204618A1 (en) Antiviral compounds
GB201209096D0 (en) Compounds
GB201217310D0 (en) Compounds
EP2699241A4 (en) Antiviral compounds
ZA201402374B (en) Antiviral compounds
GB201223429D0 (en) Compounds
GB201217290D0 (en) Compounds
GB201215284D0 (en) Compounds
GB201214250D0 (en) Compounds
GB201210968D0 (en) Compounds
GB201210364D0 (en) Compounds